Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease, and mortality in the general population
Certain SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate significant cardiovascular benefits.
The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.
Skin disorders, particularly those with known inflammatory mechanisms, may be considered potential early markers for the development of insulin resistance leading to metabolic syndrome, type 2 diabetes, and cardiovascular disease.
Hyperglycemia, obesity, and hypertriglyceridemia are negatively related to cardiovascular autonomic neuropathy indices.
The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.
Metformin improved insulin resistance regardless of baseline BMI in adolescents with type 1 diabetes.
Lower composite incidence of macrovascular events, lower incidence of coronary artery disease at 5 years
Lorcaserin reduces the risk for diabetes in obese or overweight patients with prediabetes or without diabetes and reduces HbA1c among those with diabetes.
HbA1c levels following left ventricular assist device implantation were statistically significantly lower than before surgery.
Intensive blood pressure therapy is associated with a significantly lower risk for serious cardiovascular events in the adults with diabetes.
Investigators used data from the National Health Interview Survey and follow-up mortality data to estimate trends and disparities in CVD.
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
Racial/ethnic differences were seen in the association of aldosterone with incident type 2 diabetes.
No benefit in healthy elderly patients; the protective effect is limited to those with type 2 diabetes aged 75 to 84 years.
WHO has also made recommendations for type of insulin for type 1 and type 2 diabetes in low-resource settings.
Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.
The substantial burden of cardiovascular disease in patients with diabetes has led to the exploration of various cardiovascular disease prevention strategies, including the use of aspirin.
Up-titration to a high-intensity statin occurred in only 37.7% of patients with diabetes after an acute myocardial infarction.
The risk for cardiovascular events in patients with type 2 diabetes without manifest cardiovascular disease is primarily related to the severity of atherosclerosis.
Investigators sought to compare cardiovascular risk and disease prevalence in the Hispanic and Latina population in the United States with and without a history of gestational diabetes.
While certain biomarkers are associated with eGFR decline in patients with type 2 diabetes, their predictive power is low.
Investigators examined the relationship between HbA1c with cardiovascular disease and it's subtypes.
Little or no excess risk of death, MI, or stroke in patients with type 2 diabetes who had their 5 risk factor variables within target ranges.
However, the temporary increase in type 2 diabetes risk does not attenuate benefits on total and CVD mortality.
Glucose concentration assessment before noncardiac surgery may help clinicians predict the risk for postoperative myocardial injury in patients with and without diabetes.
Diagnostic thresholds for gestational diabetes should be adapted using local populations.
A full-nut dose lowered HbA1c and estimated cholesterol levels in LDL particles of a certain diameter.
This represents the prospective study confirming an independent relationship between cardiovascular mortality and oxidative DNA damage in type 2 diabetes.
Small changes in health behaviors were seen in partners of those newly diagnosed with diabetes.
The Cardiology Advisor Articles
- Should Guidelines Use Higher Risk Thresholds When Recommending Statins for Primary CVD Prevention?
- Ezetimibe Plus Statins Modestly Reduce Cardiovascular Disease Event Risk
- ACC, AHA Publish Appropriate Use Criteria Guidelines for Peripheral Artery Intervention
- FDA: E-Liquids Found to Contain Undeclared Sildenafil and Tadalafil
- Ultrasound-Based Visualization of Silent Atherosclerosis May Improve Medication Adherence
- ACC Releases Consensus Decision Pathway for CVD Risk Reduction in T2D and ASCVD
- Childhood Behavioral Interventions May Promote Adult Cardiovascular Health
- US Medical Schools Increase in Diversity After Implementation of Accreditation Standards
- Botox Injections Explored to Reduce Postop AF in Cardiac Surgery
- AHA Scientific Statement: Low Risk of Side Effects With Statins
- Do More Aggressive Periprocedural Antibiotic Regimens Reduce Risk of Device-Related Infections?
- Adherence and Intensity of Lipid-Lowering Therapy Influence CV Risk
- Challenges in Weighing Costs, Therapeutic Benefits of Expensive Pharmaceuticals
- Sustained Systolic Blood Pressure Reductions With Barbershop Intervention
- Stethoscopes in ICU Show High Levels of Bacterial Contamination